2024 American Heart Association (Chicago)

Samer Al Said – Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy-A Prespecified Analysis of the AZALEA-TIMI 71 Trial

R obert Ariss – Trends in Temperature Control after Cardiac Arrest in Cardiac Intensive Care Units-An Analysis from the Critical Care Cardiology Trials Network Registry

David Berg – Performance of Clinician-Assigned SCAI Shock Staging in the AHA Cardiogenic Shock Registry

Prakriti Gaba – Association Between LP(a) Levels and Incident Complex Coronary Revascularization Procedures in FOURIER

Prakriti Gaba – Early Initiation of Evolocumab and Arterial Aneurysm Events in FOURIER & FOURIER-OLE

Curtis Ginder – Association between Pressure-Adjusted Heart Rate and Mortality in Cardiogenic Shock

Andreas Goette – Risk of myocardial infarction in paroxysmal vs. non-paroxysmal atrial fibrillation-an individual patient-level data analysis of 71,466 patients from COMBINE-AF

Paul Haller – Changes in high-sensitivity troponin I and associated cardiovascular risk-Analyses from the FOURIER trial in patients with stable ASCVD

Paul Haller – Galectin-3 and progression of kidney disease in patients with type 2 diabetes mellitus-Analyses from the DECLARE-TIMI 58 trial

Paul Haller – Polygenic Risk in Heart Failure

David Hamilton – Variation in Vasoactive Treatments for Cardiogenic Shock-Insights from the Critical Care Cardiology Trials Network (CCCTN)

Jason Katz – Recidivism in the Cardiac Intensive Care Unit-Insights from the Multinational Critical Care Cardiology Trials Network

Gurleen Kaur – Characterization of Isolated Right Ventricular Congestion in Cardiogenic Shock

Danny McClintick – A Polygenic Risk Score to Identify Risk of Incident Stroke and Benefit from Primary Prevention Statin Therapy

Siddharth Patel – Contemporary Practice Patterns of Vasoactive Agents in Cardiogenic Shock

Michael Rosamilia – Polygenic Risk Stratification for Risk of Venous Thromboembolism-Analysis of 31K Individuals from the Women’s Genome Health Study and JUPITER Trials